Healthcare Trends and Market Dynamics
We invite you to explore our firm’s perspective on the major developments shaping the world of healthcare and the industry leaders orchestrating those transformations. We share firsthand accounts from the entrepreneurs driving these advancements, showcasing their successes and challenges.
In addition to these real-world narratives, our research analysts are fully immersed in identifying the major trends and technological innovations that are driving change across the healthcare spectrum. Our detailed reports break down the complexities of these developments, aiding clients to pinpoint strategic investment opportunities.
Featured Podcasts
Listen in to conversations with industry leaders and innovators that are transforming the future of Healthcare
Can Clinical Trial Failure Be Insured? A Conversation with Tomas Philipson
Dr. Tomas Philipson, former Acting Chairman of the White House Council of Economic Advisers and Professor Emeritus at the University of Chicago, joins Perspectives by the Leerink Center for Pharmacoeconomics to discuss a new insurance model he developed that insures biotech investments against clinical trial failure. He explains how this insurance could reshape the way risk is managed in life sciences innovation and could expand access to capital for biotech. The second half of the episode turns to drug pricing policy where Philipson shares his perspectives on current and proposed reforms. Topics discussed include: A new insurance model for clinical trial failure, The role of AI in underwriting these insurance policies, Perspectives on the Inflation Reduction Act, Medicare drug price negotiations, and Most Favored Nation pricing, A NATO-style approach to global drug spending. Episode Links: https://www.mciuw.com/service/clinical-trial-funding-insurance/
Featured Research
Explore exclusive insights from our research team that are driving investment opportunities for discerning investors
Recent Articles
Read commentary and analysis from across Leerink Partners on markets, investing, and the Healthcare sector
Pricing the Next Wave: A Value-Centric Lens based on Historical Market Rewards
Value-Informed Price Estimates for Disease-Modifying Therapies in Primary Progressive Multiple Sclerosis
